德适生物递表港交所 华泰国际为独家保荐人

Core Viewpoint - Deshi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Company Overview - The company focuses on developing medical imaging products and services, with a product portfolio that includes six medical imaging software (including the core product AI AutoVision® and commercial product AutoVision®), three commercial medical devices, and four main reagent consumables [1] Key Product Information - The core product AI AutoVision® is a chromosome karyotype auxiliary diagnostic software that utilizes AI functionalities for intelligent analysis in prenatal diagnosis of birth defects and assisted reproductive diagnosis, demonstrating high sensitivity and specificity in multi-center clinical trials (e.g., sensitivity of 100.00% for detecting abnormal numbers, specificity of 100.00%) [1] Market Outlook - The intelligent medical imaging detection market is projected to grow significantly, with the global market expected to increase from $1.6 billion in 2024 to $25.1 billion by 2035, and the Chinese market anticipated to grow from RMB 2.4 billion in 2024 to RMB 78.1 billion by 2035, indicating a rapid growth trend [1]